Cardinal Health (CAH) Tops Q2 EPS by 11c, Trims Outlook Modestly

Cardinal Health (NYSE: CAH) reported Q2 EPS of $1.34, $0.11 better than the analyst estimate of $1.23. Revenue for the quarter came in at $33.1 billion versus the consensus estimate of $33.55 billion.

GUIDANCE:

Cardinal Health sees FY2017 EPS of $5.35-$5.50, versus the consensus of $5.44.

"Our organization has shown great resilience in the first half of our fiscal 2017. While pricing in the generic pharmaceutical market was a significant headwind for our Pharmaceutical segment profit and our enterprise operating earnings, overall we are seeing greater growth in more lines of business than we\'ve seen in some time,\" said George Barrett, chairman and CEO of Cardinal Health. "Of particular note, we saw strong growth in our Specialty Solutions group, and our Medical segment, where virtually every part of that business grew.

"As we enter the second half of the year, our organization continues to work with a clear sense of purpose – patient-centered and squarely focused on helping our partners improve the quality, safety and efficiency of the healthcare system."

For earnings history and earnings-related data on Cardinal Health (CAH) click here.

You May Also Be Interested In

• Cardinal Health (CAH) PT Raised to $250 at Mizuho
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c